XM无法为美国居民提供服务。
T
T

ThermoFisher


市场新闻

Bernstein expects a 'not so scary' Q3 for US life sciences firms

BUZZ-Bernstein expects a 'not so scary' Q3 for US life sciences firms ** Brokerage Bernstein expects a "not so scary" Q3 earnings season for U.S. life sciences and tools firms, which "would be a real treat" for investors ** "With the recovery timeline for life science tools continuing to push out (further), some investors feel like they have been t
A
I
T
W

Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show

EXCLUSIVE-Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show Thermo Fisher's Greenville, N.C. plant has been found in breach of US FDA regulations, including twice this year FDA's most recent inspection of Thermo Fisher plant found shortfalls in manufacturing of Sanofi's and AstraZeneca's Beyfortus RSV treatment Sanofi says the FDA findings were addressed and all Beyfortus doses were approved by FDA before they were shipped Adds graphic By Patrick Wingrove Oct 4 (Reu
A
S
T

Thermo Fisher falls after Reuters report on breaches at North Carolina plant

BUZZ-Thermo Fisher falls after Reuters report on breaches at North Carolina plant ** Shares of contract drug manufacturer Thermo Fisher TMO.N down 1.6% at $591.31 premarket ** One of TMO's manufacturing plants has repeatedly breached rules meant to ensure drugs are free of contamination in the last decade, Reuters repored , citing FDA documents ** The plant, located in Greenville, North Carolina is among the largest contract drug manufacturing plants in the U.S.
U
T

Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show

CORRECTED-EXCLUSIVE-Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show Corrects paragraph 26 to Novo Holdings from Novo Nordisk Thermo Fisher's Greenville, N.C. plant has been found in breach of US FDA regulations, including twice this year FDA's most recent inspection of Thermo Fisher plant found shortfalls in manufacturing of Sanofi's and AstraZeneca's Beyfortus RSV treatment Sanofi says the FDA findings were addressed and all Beyfortus doses were approved by FDA b
A
S
T

Thermo Fisher Scientific Expands Oral Solid Dose Development And Manufacturing Capabilities Across North America

BRIEF-Thermo Fisher Scientific Expands Oral Solid Dose Development And Manufacturing Capabilities Across North America Sept 26 (Reuters) - Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC EXPANDS ORAL SOLID DOSE DEVELOPMENT AND MANUFACTURING CAPABILITIES ACROSS NORTH AMERICA Source text for Eikon: ID:nBwc3wlpHa Further company coverage
T

ASML supplier NTS Group opens Singapore plant

ASML supplier NTS Group opens Singapore plant AMSTERDAM, Sept 20 (Reuters) - NTS Group, a Dutch-based maker of "mechatronic" equipment used by semiconductor firms including neighbouring giant ASML ASML.AS , on Friday opened a major new assembly and manufacturing plant in Singapore. Mechatronics integrate mechanical, electronics and software systems. NTS is known as a supplier of highly complex systems used in metrology, where top names include Lam Research, Applied Materials AMAT.O , Thermo Fish
A
L
T

U.S. Factset, FedEx, Thermo Fisher Scientific

U.S. RESEARCH ROUNDUP-Factset, FedEx, Thermo Fisher Scientific Sept 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Factset, FedEx and Thermo Fisher Scientific on Friday. HIGHLIGHTS * Arthur J. Gallagher & Co. AJG.N : RBC raises target price to $320 from $310 * Factset FDS.N : RBC raises target price to $503 from $464 * FedEx Corp FDX.N : Baird cuts target price to $320 from $340 * IQVIA Holdings Inc IQV.N : Baird
A
A
A
B
D
E
N
X
T
A
D
I
L
P

U.S. Constellation Energy, Eli Lilly, Talen Energy

U.S. RESEARCH ROUNDUP-Constellation Energy, Eli Lilly, Talen Energy Sept 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Constellation Energy, Eli Lilly and Talen Energy, on Friday. HIGHLIGHTS * Constellation Energy Corp CEG.O : Jefferies initiates with hold rating; target $183 * Eli Lilly LLY.N : JP Morgan raises target price to $1,100 from $1,050 * Moderna MRNA.O : JP Morgan cuts to underweight from neutral * Vo
A
C
C
F
F
H
H
H
I
K
W
F
D
T
Z
A
A
D
E
H
L

Buyout barons’ dirty secret shows hard times ahead

BREAKINGVIEWS-Buyout barons’ dirty secret shows hard times ahead The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Liam Proud LONDON, Sept 12 (Reuters Breakingviews) - Private-equity dealmakers like to boast about the ways they improve companies, like supercharging growth or trimming costs. The evidence, however, suggests that buyout barons owe a large chunk of their success to rising valuation multiples instead.
U
T

Agilent beats quarterly results on strong demand from biotech clients

Agilent beats quarterly results on strong demand from biotech clients Aug 21 (Reuters) - Agilent Technologies A.N on Wednesday beat Wall Street estimates for third-quarter profit and revenue, banking on strong demand for its medical tools and equipment used in clinical studies. "While market conditions continued to be challenged during the quarter, we saw steady signs of improvement as anticipated", said CEO Padraig McDonnell.
A
T

Bio-Techne meets Q4 profit estimates on demand for its diagnostics products

Bio-Techne meets Q4 profit estimates on demand for its diagnostics products Aug 7 (Reuters) - Bio-Techne TECH.O reported fourth-quarter profit in line with estimates on Wednesday as growth in the diagnostics and genomics unit offset weakness in its protein sciences unit. The Minnesota-based company posted an adjusted profit of 49 cents per share, meeting analysts' expectations according to LSEG data.
T

Leerink views Lilly and Sarepta as defensive stocks in turbulent market

BUZZ-Leerink views Lilly and Sarepta as defensive stocks in turbulent market ** Brokerages Leerink Partners says Eli Lilly LLY.N and Sarepta Therapeutics SRPT.O are among stocks it expects to outperform the broader market in "this turbulent period" of recession concerns ** Brokerage expects strong performance from the weight-loss and diabetes drug maker LLY on Wed, when it reports its earnings ** SRPT is a "a potential haven for investors seeking downside protection in a choppy market" due to po
A
B
M
T

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims

UPDATE 1-Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims Adds response from Novartis in paragraph 3 By Blake Brittain Aug 5 (Reuters) - Novartis NOVN.S and Viatris VTRS.O were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.
N
T

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims By Blake Brittain Aug 5 (Reuters) - Novartis NOVN.S and Viatris VTRS.O were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development. The estate of Henrietta Lacks accused Novartis and Viatris of unlawfully profiting from the use of the "HeLa" cells to create drugs that have been "integral to their market pre
N
T

China's stuttering recovery darkens global corporate growth outlook

ANALYSIS-China's stuttering recovery darkens global corporate growth outlook By Medha Singh Aug 2 (Reuters) - Global burger chains to car manufacturers are increasingly feeling the pinch from a faltering recovery in the world's No. 2 economy , China, and are strapping in for a bumpy ride ahead. A protracted downturn in the property market and high levels of job insecurity have knocked the wind out of a fragile recovery in China, a global trading powerhouse, and the effects of its slowdown can be
A
B
B
B
H
K
L
L
M
P
Q
S
T
T

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products Aug 1 (Reuters) - Bio-Rad Laboratories BIO.N cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients. Shares of the diagnostics company fell 20% after the bell. Bio-Rad expects its full-year 2024 adjusted revenue to decline by about 2.5% to 4% on a currency-neutral basis, compared to its previous estimate of 1.0% to 2.5%.
T
W

Waters Corp cuts annual profit forecast on weak demand for lab equipment

Waters Corp cuts annual profit forecast on weak demand for lab equipment July 31 (Reuters) - Waters Corp WAT.N lowered its annual profit forecast as it anticipates reduced demand for its products and services used in drug development and research. Milford, Massachusetts-based Waters supplies lab equipment and technology for scientists across the world, with the majority of its revenue coming in from biopharma clients who use its tools for research and drug development.
T
W

Street View: Thermo's solid quarter signals easing demand weakness

BUZZ-Street View: Thermo's solid quarter signals easing demand weakness ** Thermo Fisher TMO.N raised its annual profit outlook on Wednesday and posted a better-than-expected profit in the second quarter, banking on improved demand for its tools and services used in clinical trials. SOLID QUARTER BY TMO SIGNALS RECOVERY ** RBC Capital Markets ("out
T

U.S. STOCKS Tesla, Lamb Weston, Blackstone Mortgage Trust

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Lamb Weston, Blackstone Mortgage Trust Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq plummeted to a one-month low on Wednesday after Tesla and Alphabet disappointed with lackluster earnings, prompting investors to question if the Big Tech and AI-fueled 2024 equity rally was sustainable in the long run.
A
C
F
G
M
S
S
T
V
C
T
U
U
E
T
L
O

U.S. STOCKS FTAI Aviation, Check Point, Sage Therapeutics

BUZZ-U.S. STOCKS ON THE MOVE-FTAI Aviation, Check Point, Sage Therapeutics Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street fell on Wednesday, with the tech-heavy Nasdaq leading declines after lackluster quarterly results from Tesla and Alphabet raised questions about the sustainability of the Big Tech and AI-led 2024 equity rally.
A
F
G
M
S
T
V
C
T
U
U
E
T
L
O



商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明